Innovent Biologics valuation
$85.80Change from previous close: +2.26%Absolute change: +$1.90
Valuation
The P/E ratio is 111.5. The average price target of 28 analysts is $130.22.
Data as of November 16, 2026
Innovent Biologics compared with similar companies
Innovent Biologics's P/E (trailing 12 months): 111.5, +179% against the median of a group of 8 similar companies (40.0).
| Metric | Innovent Biologics | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 111.5 | 40.0 | 34.2 – 60.9 | High |
| Forward P/E | 33.6 | 32.0 | 27.9 – 49.3 | Middle |
| EV/EBITDA | 71.9 | 29.4 | 22.9 – 71.9 | Middle |
| Price/book | 6.04 | 6.04 | 3.07 – 9.42 | Middle |
| Price/sales | 9.41 | 10.9 | 8.78 – 35.3 | Middle |
| Gross margin | 76.5% | 73.6% | 53.1% – 76.9% | Middle |
| Operating margin | 7.4% | 21.1% | 10.7% – 32.0% | Low |
| Net margin | 7.8% | 11.1% | 7.2% – 26.8% | Middle |
| ROE | 7.0% | 10.4% | 5.0% – 16.3% | Middle |
| Debt/equity | 0.11 | 0.15 | 0.07 – 0.38 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Other metrics
Valuation multiples
- Market cap
- $147.79B
- Enterprise value
- $129.64B
- PEG
- 0.75
- EV/revenue
- 8.25
Profitability and growth
- ROA
- 2.2%
- ROIC
- 3.6%
- Revenue growth (year over year)
- 44.8%
- Earnings growth (year over year)
- 42.9%
Financial health
- Total cash
- $20B
- Total debt
- $2.32B
- Current ratio
- 2.68
- Quick ratio
- 2.35
- Altman Z-Score
- 4.34
- Piotroski F-Score
- 6.00
Dividends
- Dividend yield
- 0.0%
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $130.22
- Median price target
- $128.72
- High price target
- $156.92
- Low price target
- $94.81
- Analysts with a price target
- 28
- Consensus
- Strong buy
- Forward EPS
- $2.52
- EPS estimate, current year
- $1.41
Shares and trading
- Beta
- 0.37
- Average volume
- 11.71M
- Shares outstanding
- 1.74B
- Float
- 1.61B
- Institutional ownership
- 58.7%
- Insider ownership
- 6.2%
